Celgene (NASDAQ:CELG) has been assigned a $152.00 price target by stock analysts at Guggenheim in a report released on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective suggests a potential upside of 42.10% from the company’s previous close.
A number of other equities research analysts also recently weighed in on the stock. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Thursday, October 5th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price objective on shares of Celgene in a research report on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $134.92.
Celgene (NASDAQ CELG) traded up $0.64 on Monday, hitting $106.97. 2,687,543 shares of the stock traded hands, compared to its average volume of 4,825,260. The company has a market cap of $83,720.00, a P/E ratio of 25.23, a P/E/G ratio of 0.82 and a beta of 1.77. Celgene has a one year low of $94.55 and a one year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Several large investors have recently modified their holdings of CELG. Neuberger Berman Group LLC lifted its stake in Celgene by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC acquired a new stake in Celgene during the second quarter valued at approximately $3,616,000. Lincoln Capital Corp lifted its stake in Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the last quarter. RiverPoint Capital Management LLC lifted its stake in Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares during the last quarter. Finally, Iguana Healthcare Management LLC lifted its stake in Celgene by 12.5% during the first quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after purchasing an additional 10,000 shares during the last quarter. 79.74% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first reported by American Market News and is owned by of American Market News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/26/celgene-celg-given-a-152-00-price-target-by-guggenheim-analysts.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
